Naratriptan has been approved in the United States

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Naratriptan studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
105818 IV A post-marketing surveillance (PMS) study to monitor the safety of Naramig (Naratriptan) administered in Korean subjects according to the prescribing information.
EPI40050 IV The Sumatriptan and Naratriptan Pregnancy Registry
S2W20006 IV A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria.
S2W40010 IV A randomised, double-blind, cross-over study to compare the patient preference of oral Naratriptan (NaramigÔ) 2.5mg with Naproxen 500mg in patients dissatisfied with simple analgesics in the treatment of acute migraine.
S2W40012 IV A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine
S2W40024 IV A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine
S2W40027 IV An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine
S2W40028 IV A multicentre, open label trial to evaluate patient preference for Amerge® 2.5 mg in the acute treatment of migraine.
S2WA4002 IV A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
S2WA4003 IV A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4004 IV A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Compared to Oral Naproxen Sodium (275mg) on Migraine-Related Quality of Life.
S2WA4005 IV A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5mg) Administered Twice Daily in the Treatment of Transformed Migraine.
S2WA4006 IV A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg and 2.5mg twice daily as prophylactic treatment for menstrually-associated migraine.
S2WB4001 IV A randomised double-blind, cross-over study to investigate patient overall satisfaction with efficacy and tolerability of oral Naratriptan 2.5mg Vs oral Sumatriptan 50mg for the treatment of patients who lapse from 100mg oral or 6mg subcutaneous Sumatriptan use.
S2W30018 III An open study of the efficacy and tolerability of naratriptan in prophylactic treatment of pure menstrual migraine attacks
S2W40031(NARF4011) III A double-blind, randomised, parallel-group design, placebo-controlled study of the effects of naratriptan tablets 2.5mg in treatment of menstrually-associated migraine attack at a stage of mild pain.
S2WA3001 III A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of four doses of oral naratriptan in the acute treatment of a single migraine attack.
S2WA3003 III A randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of oral naratriptan in the acute treatment of four migraine attacks.
S2WA3012 III A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and tolerability of oral naratriptan in an adolescent migraine population.
S2WB3004 III An open study of the long-term safety and efficacy of oral naratriptan 2.5mg in the acute treatment of migraine.
S2WB3011 III A randomised, double-blind, two attack, cross-over study to compare the efficacy, safety and tolerability of oral naratriptan 2.5mg with oral sumatriptan 100mg in the acute treatment of migraine in patients susceptible to headache recurrence.
S2WB2003 (S2WT50) II A double-blind, placebo-controlled, randomised, parallel group study to evaluate the safety and efficacy of oral naratriptan (5mg and 10mg) following dosing during a migraine attack.
S2WB2004 (S2WBT51) II A double-blind, randomised, placebo-controlled, parallel group study to compare the efficacy and safety of oral naratriptan (1mg-10mg) with that of oral sumatriptan (100mg) and placebo in the acute treatment of migraine headache.
S2WB3002 II A randomised, double-blind, placebo-controlled, oral sumatriptan-controlled (100mg), three attack, parallel group study to determine the efficacy, safety and tolerability of oral naratriptan (0.1mg, 0.25mg, 1.0mg and 2.5mg) in the acute treatment of migraine headache.
548-01 I GG548 (naratriptan) Phase I study (single oral dose study in healthy male volunteers).
C93-060 I A study to investigate the safety, tolerability, pharmacodynamic and pharmacokinetic response to two doses of oral GR85548A separated by 4 hours.
C93-070 I A study to investigate the dose proportionality of oral tablet GR85548A pharmacokinetics in healthy female volunteers.
C93-081 I A study to investigate the pharmacokinetics of oral GR85548 in subjects with impaired renal function.
C93-087 I A study to investigate whether alcohol has an effect on the safety, tolerability, pharmacokinetics or pharmacodynamics of GR85548.
C94-034 I A study to determine the absolute bioavailability of oral GR85548A.
C94-036 I An ascending dose, parallel group study to compare the effects of oral GR85548A on blood pressure in healthy subjects and in hypertensive patients taking anti-hypertensive therapy.
C94-045 I A study to investigate the potential central function effect of GR85548.
C94-071 I A study to investigate the safety, tolerability and pharmacokinetics of repeat dosing with oral GR85548A for 5 days.
C95-036 I A study to investigate the pharmacokinetics of oral naratriptan (GR85548A) in subjects with impaired hepatic function.
S2WA1002 I A study to evaluate the pharmacokinetics of two doses of 1.0mg, 2.5mg and 5.0mg GR85548A tablets separated by 2 hours in healthy volunteers.
S2WA1003 I A study to determine the effect of food on the pharmacokinetics of oral naratriptan tablets in healthy female volunteers
S2WA1004 I A comparative study of the pharmacologic effects of naratriptan, codeine and placebo in experienced psychoactive substance users.
S2WA1007 I A study to evaluate the pharmacokinetics and pharmacodynamics of oral naratriptan in migraine subjects.
S2WA1010 (534/040) I A study to investigate the interaction of naratriptan and dihydroergotamine in healthy volunteers.
S2WA1011 (534/050) I A study to investigate the interaction of naratriptan and ergotamine in healthy volunteers.
S2WA1012 (C95-072) I A study to investigate the pharmacokinetics of oral naratriptan in adolescent migraine patients outside a migraine attack.
S2WB1002 I A study to compare the safety, tolerability, pharmacodynamics and pharmacokinetics of two doses of oral naratriptan (GR85548A) in young and elderly subjects.
S2WB1003 (C95-035) I A study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan.
S2WB1006 (C95-071) I A study to evaluate the ocular effects of naratriptan in healthy subjects.
S2WB3009 I A study to assess the effect of 1.5mg subcutaneous naratriptan (GR85548A) on cardiac haemodynamics in patient-volunteers with existing or suspected coronary artery disease.